Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AHK-Cu and Thymosin Alpha-1 — mechanism, side effects, legal status, and pricing.
AHK-Cu is a copper-binding tripeptide (Ala-His-Lys-Cu) structurally related to GHK-Cu, studied in dermatological research for its role in extracellular matrix remodeling and hair follicle signaling.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) corresponding to the N-terminus of prothymosin α. Marketed as Zadaxin / thymalfasin and approved in 35+ countries for chronic hepatitis B/C and as an immune adjuvant, but NOT FDA-approved in the US — Phase 3 HCV trials ended without approval. Outside the US it is one of the most clinically validated immune-modulating peptides.
AHK-Cu
Thymosin Alpha-1
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AHK-Cu
Thymosin Alpha-1
COA corpus from Disclosed Labs — independently tested batches only.
AHK-Cu
14
COAs
99.6%
Avg purity
5
Labs
Thymosin Alpha-1
69
COAs
99.6%
Avg purity
12
Labs
Pyo et al. (Archives of Pharmacal Research, 2007) reported that AHK-Cu stimulated elongation of human hair follicles ex vivo, promoted proliferation of dermal papilla cells, and increased VEGF secretion while reducing TGF-beta1 in cultured fibroblasts. Evidence is preclinical only; no controlled clinical trials have been published.
Thymosin alpha-1 has been studied in 90+ clinical trials. A meta-analysis by Yang et al. (Antiviral Research 2008, PMID 18078676) in chronic hepatitis B found antiviral efficacy comparable to interferon-alpha. Tuthill, Rios & McBeath (Ann N Y Acad Sci 2010, PMID 20536460) reviewed the global Zadaxin program across HBV, HCV, melanoma, HCC, and vaccine adjuvancy. Romani et al. (Blood 2006, PMID 16741252) established the TLR9 / IDO dendritic-cell mechanism that underlies Ta1's dual pro-inflammatory / tolerogenic effects. During the COVID-19 pandemic, Liu et al. (Clin Infect Dis 2020, PMID 32442287) reported reduced mortality (11.11% vs 30.00%, p=0.044) in severe lymphopenic COVID-19 patients via restoration of exhausted T cells. A 2024 systematic review by Dinetz & Lee (Altern Ther Health Med, PMID 38308608) covering 30+ trials and 11,000+ subjects concluded Ta1 is a well-tolerated and effective immune modulator, and argued the FDA's 2023 restriction appeared unfounded given the clinical evidence. US regulatory status: NOT FDA-approved; removed from 503A Category 2 in September 2024 after nominator withdrawal; PCAC voted AGAINST inclusion on the 503A Bulks List on December 4, 2024.
AHK-Cu (Cosmetic) and Thymosin Alpha-1 (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs